US · FBIOP · BIOTECHNOLOGY
Fortress Biotech, Inc. (FBIOP) intrinsic value and stock valuation
$13.60as of 2026-11-21 · Mkt cap 150.99M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Fortress Biotech, Inc. DCF and intrinsic value
InvestorsCraft values FBIOP with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from FBIOP’s statements →
Fortress Biotech, Inc. Graham Number
Graham Number: $3.50d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $63.3M | $57.7M | $84.5M | $75.7M | $68.8M |
| Operating income | -$-70.22M | -$-110.38M | -$-142.34M | -$-203.56M | -$-188.54M |
| Net income | $6.82M | -$-46M | -$-60.64M | -$-86.58M | -$-64.7M |
| EPSd | $24.4K | -$-2.21M | -$-7.48M | -$-14.63M | -$-11.87M |
| Operating cash flow | -$-65.78M | -$-80.19M | -$-128.22M | -$-179.4M | -$-116.54M |
| Capital expenditure | $0.00 | -$-15M | -$-8.1M | -$-3.06M | -$-16.35M |
| Free cash flow | -$-65.78M | -$-95.19M | -$-136.32M | -$-182.46M | -$-132.89M |
| Total assets | $185.6M | $144.2M | $167.5M | $294.3M | $396.5M |
| Total debt | $74.3M | $76M | $84.7M | $127.3M | $75M |
| Net debt | -$-5.08M | $18.7M | $3.73M | -$-50.92M | -$-230.77M |
| Total equity | $62.2M | -$-1.64M | $1.59M | $50M | $225.9M |
| Cash and short-term investments | $79.4M | $57.3M | $80.9M | $178.3M | $305.7M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $63.3M | $57.7M | $84.5M | $75.7M | $68.8M |
| Cost of revenue | $20.9M | $20.9M | $22.9M | $30.8M | $32.1M |
| Gross profit | $42.3M | $36.8M | $61.6M | $45M | $36.7M |
| Research and development expenses | $11.9M | $56.9M | $106.1M | $134.9M | $128.9M |
| Selling, general and administrative expenses | $96.4M | $87.7M | $91M | $113.7M | $86.8M |
| Other expenses | $4.26M | $2.56M | $6.91M | $0.00 | $9.54M |
| Operating expenses | $112.6M | $147.2M | $204M | $248.5M | $225.3M |
| Cost and expenses | $133.5M | $168.1M | $226.9M | $279.3M | $257.3M |
| Interest income | $2.48M | $2.68M | $3M | $1.4M | $650K |
| Interest expense | $8.71M | $9.93M | $12.5M | $13.6M | $15.3M |
| Depreciation and amortization | $4.66M | $4.46M | $6M | $9.35M | $6.79M |
| Ebitda | -$-20.16M | -$-104.49M | -$-135.72M | -$-193.69M | -$-146.17M |
| Operating income | -$-70.22M | -$-110.38M | -$-142.34M | -$-203.56M | -$-188.54M |
| Total other income/expenses, net | $36.7M | -$-10.16M | -$-11.29M | -$-9.9M | $24.2M |
| Income before tax | -$-33.53M | -$-120.54M | -$-153.63M | -$-213.46M | -$-164.35M |
| Income tax expense | -$-620K | $310K | $520K | $450K | $470K |
| Net income | $6.82M | -$-46M | -$-60.64M | -$-86.58M | -$-64.7M |
| Weighted average shares outstanding | $27.9M | $20.8M | $8.11M | $5.92M | $5.45M |
| Weighted average diluted shares outstanding | $279M | $20.8M | $8.11M | $5.92M | $5.45M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $79.4M | $57.3M | $80.9M | $178.3M | $305.7M |
| Net receivables | $29.9M | $10.4M | $15.4M | $28.4M | $23.8M |
| Inventory | $9.62M | $14.4M | $10.2M | $14.2M | $9.86M |
| Total current assets | $123.8M | $90.4M | $117M | $230.4M | $346.5M |
| Property, plant and equipment, net | $14.8M | $17.1M | $23.5M | $33M | $34.1M |
| Goodwill and intangible assets | $27.6M | $31.9M | $20.3M | $27.2M | $12.6M |
| Long-term investments | $17.7M | $1.55M | $2.44M | $2.69M | $2.22M |
| Total non-current assets | $61.7M | $53.9M | $50.5M | $63.9M | $50M |
| Total assets | $185.6M | $144.2M | $167.5M | $294.3M | $396.5M |
| Accounts payable | $14.2M | $31.6M | $34.8M | $57.2M | $47.4M |
| Short-term debt | $2.13M | $3.25M | $5.52M | $12.6M | $7.43M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $730K | $2.61M |
| Total current liabilities | $49.7M | $71.4M | $84.9M | $127.7M | $101M |
| Long-term debt | $72.2M | $72.7M | $79.1M | $114.7M | $67.6M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $73.6M | $74.5M | $81M | $116.6M | $69.6M |
| Capital lease obligations | $14.8M | $17.4M | $20.8M | $24M | $23.1M |
| Total liabilities | $123.4M | $145.9M | $165.9M | $244.3M | $170.6M |
| Common stock | $30K | $30K | $10K | $110K | $100K |
| Retained earnings | -$-734.05M | -$-740.87M | -$-694.87M | -$-634.23M | -$-547.46M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $62.2M | -$-1.64M | $1.59M | $50M | $225.9M |
| Total investments | $17.7M | $1.55M | $2.44M | $2.69M | $2.22M |
| Total debt | $74.3M | $76M | $84.7M | $127.3M | $75M |
| Net debt | -$-5.08M | $18.7M | $3.73M | -$-50.92M | -$-230.77M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-32.91M | -$-120.86M | -$-154.15M | -$-213.91M | -$-164.83M |
| Depreciation and amortization | $4.66M | $4.46M | $6M | $9.35M | $6.79M |
| Stock-based compensation | $28.7M | $32.6M | $17M | $23M | $19.5M |
| Change in working capital | -$-25.1M | -$-8.13M | -$-12.52M | -$-710K | $36.4M |
| Accounts receivable | -$-19.33M | $4.47M | $12.5M | -$-4.84M | $830K |
| Inventory | $4.81M | -$-4.22M | $3.95M | $1.74M | -$-8.46M |
| Accounts payable | -$-7.97M | -$-6.39M | -$-24.38M | $8.35M | $43.3M |
| Net cash provided by operating activities | -$-65.78M | -$-80.19M | -$-128.22M | -$-179.4M | -$-116.54M |
| Investments in property, plant and equipment | $0.00 | -$-15M | -$-60K | -$-2.71M | -$-4.57M |
| Acquisitions, net | $8.96M | $0.00 | $0.00 | -$-20M | $56.9M |
| Net cash used for investing activities | $10.1M | -$-15M | -$-2.1M | -$-22.93M | $40.5M |
| Common stock issued | $84.6M | $82.8M | $80.4M | $40.3M | $155.3M |
| Common stock repurchased | -$-270K | $0.00 | $0.00 | -$-1.11M | $0.00 |
| Dividends paid | -$-660K | -$-4.71M | -$-8.77M | -$-8.78M | -$-8.78M |
| Net cash used for financing activities | $77.4M | $70.6M | $32.7M | $75.3M | $149M |
| Net change in cash | $21.8M | -$-24.55M | -$-97.59M | -$-127.01M | $73M |
| Cash at end of period | $80.6M | $58.8M | $83.4M | $181M | $308M |
| Operating cash flow | -$-65.78M | -$-80.19M | -$-128.22M | -$-179.4M | -$-116.54M |
| Capital expenditure | $0.00 | -$-15M | -$-8.1M | -$-3.06M | -$-16.35M |
| Free cash flow | -$-65.78M | -$-95.19M | -$-136.32M | -$-182.46M | -$-132.89M |
Line items
Line items
Line items
About Fortress Biotech, Inc.
Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi for inflammatory lesions of rosacea; Exelderm, an antifungal cream and solution for topical use; Targadox, an oral doxycycline drug for therapy for severe acne; and Luxamend, a water-based emulsion to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, sunburns, and radiation dermatitis. It also develops intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for Menkes disease; UNLOXCYT for metastatic cutaneous squamous cell carcinoma; Olafertinib for EGFR mutation-positive NSCLC; CAEL-101, a monoclonal antibody for amyloid light chain amyloidosis; and Triplex, a cytomegalovirus vaccine. In addition, the company's early-stage product candidates include Dotinurad for gout; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma and anaplastic astrocytoma; MB-106 for B-cell non-hodgkin lymphoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. Further, its preclinical product candidates comprise AAV-ATP7A and AVTS-001 gene therapies; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
- CEO
- Lindsay A. Rosenwald
- Employees
- 78
- Beta
- 1.21
Explore
Frequently asked questions
What is the intrinsic value of Fortress Biotech, Inc. (FBIOP)?
InvestorsCraft does not currently publish an intrinsic value for FBIOP. How the IC value is calculated.
Is FBIOP undervalued?
InvestorsCraft does not publish an undervaluation signal for FBIOP at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.